Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 674 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Atopic Hypersensitivity Clear all
Completed No phase listed Observational Accepts healthy volunteers

Histamine Pharmacogenetics in Children With Atopic Dermatitis

NCT00277433
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Buccal Swab
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
6 Months to 5 Years
Enrollment
751 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
7
States / cities
Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 3, 2026, 9:26 AM EDT
Completed Phase 3 Interventional Results available

Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT02277743
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Placebo (for Dupilumab)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
45
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Sep 3, 2026, 9:26 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05633355
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 17 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Phoenix, Arizona • Tempe, Arizona • Bryant, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 3, 2026, 9:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project

NCT06300697
View directory record Official record
Conditions
Atopic Dermatitis, Food Allergy, Healthy
Interventions
Data and biospecimen collection, Skin biopsies, Oral Food Challenge (OFC) procedures
Other
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 3, 2026, 9:26 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Identification of Epidermal Signatures in Patients With Atopic Dermatitis

NCT02680405
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Skin Biopsy, Skin tape stripping, Blood draw
Procedure
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Sep 3, 2026, 9:26 AM EDT
Active, not recruiting No phase listed Observational

Observational Evaluation of Atopic Dermatitis in Pediatric Patients

NCT03687359
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Standard of care
Other
Lead sponsor
Sanofi
Industry
Eligibility
0 Years to 11 Years
Enrollment
1,860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2035
U.S. locations
46
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 3, 2026, 9:26 AM EDT
Not yet recruiting Phase 4 Interventional

Opzelura Experience Study

NCT07661979
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ruxolitinib, ruxolitinib and an Eczema Action Plan
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 3, 2026, 9:26 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis

NCT02595073
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DSXS, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
6 Months and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 3, 2026, 9:26 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety/Tolerability of Grass MATA MPL

NCT00414141
View directory record Official record
Conditions
Type I Hypersensitivity
Interventions
Grass MATA MPL, Placebo
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 59 Years
Enrollment
1,028 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
65
States / cities
Colorado Springs, Colorado • Denver, Colorado • Englewood, Colorado + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2010 · Synced Sep 3, 2026, 9:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Molecular and Cellular Characterization of Spongiotic Dermatitis

NCT00371163
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis, Contact Dermatitis
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Sep 3, 2026, 9:26 AM EDT
Terminated Phase 3 Interventional

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05882877
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 100 Years
Enrollment
2,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
136
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 3, 2026, 9:26 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis

NCT01577628
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, Asthma, Food Allergies, Allergic Rhinitis
Interventions
Lipikar Balm AP
Drug
Lead sponsor
Cosmetique Active International
Industry
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Canton, Michigan • Fort Gratiot, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Sep 3, 2026, 9:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

NCT04313400
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
1.1% w/w AMTX-100 CF-part1, Placebo, 1.1% w/w AMTX-100 CF3-part2
Drug
Lead sponsor
Amytrx Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Cerritos, California • Encino, California • Long Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 3, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route

NCT00614731
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
KLH carrier-protein
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 3, 2026, 9:26 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Evaluating the Effects of Cleansers on the Skin

NCT03188653
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
CeraVe® Eczema Soothing Body Wash, Cetaphil® RestoraDerm® Eczema Calming Body Wash, Dove® Sensitive Skin Body Wash, Eucerin® Skin Calming Body Wash, Aveeno® Skin Relief Body Wash, MooGoo® Milk Wash, Free & Clear Liquid Cleanser
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Sep 3, 2026, 9:26 AM EDT
Completed Phase 2 Interventional

Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus

NCT00838708
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
SRD174 Cream, vehicle cream
Drug · Other
Lead sponsor
Serentis Ltd.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
13
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Oceanside, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2009 · Synced Sep 3, 2026, 9:26 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

NCT06238765
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
CorEvitas
Network
Eligibility
10 Years to 15 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2099
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 3, 2026, 9:26 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

NCT03349060
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Birmingham, Alabama • Encinitas, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 3, 2026, 9:26 AM EDT
Completed Phase 2 Interventional Results available

A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

NCT05656911
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Zabedosertib (BAY1834845), Placebo to zabedosertib (BAY1834845)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Skokie, Illinois • Boston, Massachusetts • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Sep 3, 2026, 9:26 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.

NCT04250337
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo, Topical Corticosteroid
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
43
States / cities
Scottsdale, Arizona • Anaheim, California • Bakersfield, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 3, 2026, 9:26 AM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

NCT06055361
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
BxC-I17e (primed iMSC derived Extracellular vesicles(EV)), Placebo
Drug
Lead sponsor
Brexogen Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
North Little Rock, Arkansas • Camp Hill, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 3, 2026, 9:26 AM EDT
Completed Phase 4 Interventional Results available

Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)

NCT00367016
View directory record Official record
Conditions
Asthma, Allergic Rhinitis, Atopic Dermatitis
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 3, 2026, 9:26 AM EDT
Completed No phase listed Observational

Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis

NCT00379678
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 3, 2026, 9:26 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

NCT02925793
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DS107, Vehicle cream
Drug · Other
Lead sponsor
DS Biopharma
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Sep 3, 2026, 9:26 AM EDT